These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25288420)

  • 1. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
    Starner CI; Alexander GC; Bowen K; Qiu Y; Wickersham PJ; Gleason PP
    Health Aff (Millwood); 2014 Oct; 33(10):1761-9. PubMed ID: 25288420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
    Doshi JA; Li P; Ladage VP; Pettit AR; Taylor EA
    Am J Manag Care; 2016 Mar; 22(3):188-97. PubMed ID: 27023024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
    Karmarkar TD; Starner CI; Qiu Y; Tiberg K; Gleason PP
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP191-7. PubMed ID: 27266948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
    Yeung K; Barthold D; Dusetzina SB; Basu A
    N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
    Sensharma A; Yabroff KR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The redesign of consumer cost sharing for specialty drugs at the California Health Insurance Exchange.
    Robinson J; Price A; Goldman Z
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s87-91. PubMed ID: 27270158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Insurers Often Foot Bill When Drug Coupons Are Used.
    Wolinsky H
    Manag Care; 2017 Mar; 26(3):38-39. PubMed ID: 28510519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use.
    Robinson JC; Howell S
    Health Aff (Millwood); 2014 Oct; 33(10):1745-50. PubMed ID: 25288418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Copayment Offsets for Prescription Drugs in the United States.
    Sen AP; Kang SY; Rashidi E; Ganguli D; Anderson G; Alexander GC
    JAMA Intern Med; 2021 Jun; 181(6):758-764. PubMed ID: 33779680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study.
    Daubresse M; Andersen M; Riggs KR; Alexander GC
    Pharmacotherapy; 2017 Jan; 37(1):12-24. PubMed ID: 27455456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
    Brouwer E; Yeung K; Barthold D; Hansen R
    J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?
    Sarnak DO; Squires D; Kuzmak G; Bishop S
    Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.
    Dusetzina SB
    Health Aff (Millwood); 2016 Jul; 35(7):1241-6. PubMed ID: 27385240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.